| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PROTAC Sirt2 Degrader-1 is a novel, potent PROTAC (proteolysis targeting chimera) which was identified based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand. In its capacity as a Sirt2 degrader, PROTAC Sirt2 Degrader-1 exhibits an IC50 of 0.25 μM for Sirt2, while having no effect on Sirt1/Sirt3 (IC50s > 100 μM). The highly adaptable linking strategy and azide derived from thalidomide can be easily applied to alkynylated ligands of other targets. The HeLa cell undergoes hyperacetylation and enhanced process elongation due to isotype-selective Sirt2 degradation induced by PROTAC Sirt2 Degrader-1. With regard to the ability to chemically induce the degradation of an epigenetic eraser protein, PROTAC Sirt2 Degrader-1 is the first example of a probe.
| Targets |
SIRT2 ( IC50 = 0.25 μM )
|
|---|---|
| ln Vitro |
In HeLa cells, Sirt2 degradation is induced by PROTAC Sirt2 Degrader-1 (Compound 12; 10 μM, 1-6 hours) [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HeLa cells Tested Concentrations: 10 µM Incubation Duration: 1-6 hrs (hours) Experimental Results: Causes degradation of Sirt2, but has no effect on Sirt1 levels. |
| References |
| Molecular Formula |
C40H40N10O8S2
|
|---|---|
| Molecular Weight |
852.937805175781
|
| Exact Mass |
852.25
|
| Elemental Analysis |
C, 56.33; H, 4.73; N, 16.42; O, 15.01; S, 7.52
|
| CAS # |
2098487-75-1
|
| PubChem CID |
135397670
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
60
|
| Complexity |
1540
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
GRYRXFYWVDWPQY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C40H40N10O8S2/c1-23-15-24(2)44-40(43-23)59-22-34(53)46-39-42-18-28(60-39)17-25-7-5-8-27(16-25)57-20-26-19-49(48-47-26)14-4-3-13-41-33(52)21-58-31-10-6-9-29-35(31)38(56)50(37(29)55)30-11-12-32(51)45-36(30)54/h5-10,15-16,18-19,30H,3-4,11-14,17,20-22H2,1-2H3,(H,41,52)(H,42,46,53)(H,45,51,54)
|
| Chemical Name |
N-[4-[4-[[3-[[2-[[2-(4,6-dimethylpyrimidin-2-yl)sulfanylacetyl]amino]-1,3-thiazol-5-yl]methyl]phenoxy]methyl]triazol-1-yl]butyl]-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetamide
|
| Synonyms |
Sirt2-PROTAC-1; Sirt2 PROTAC-1; Sirt2-PROTAC1; Sirt2 PROTAC 1; PROTAC Sirt2 Degrader 1; PROTAC Sirt2 Degrader-1
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~117.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1724 mL | 5.8621 mL | 11.7242 mL | |
| 5 mM | 0.2345 mL | 1.1724 mL | 2.3448 mL | |
| 10 mM | 0.1172 mL | 0.5862 mL | 1.1724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 J Med Chem.2018 Jan 25;61(2):482-491. |
|---|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA